Kristina Fanucci
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kristina Fanucci as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07222215 · PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Kristina A. Fanucci · recruiting · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT07198724 · ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerKristina A. Fanucci · recruiting · Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:05 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.Cancer Res Commun · 202333 citationsRCR 2.6
- Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.Breast Cancer Res · 20252 citationsRCR 0.7